<DOC>
	<DOCNO>NCT00079469</DOCNO>
	<brief_summary>RATIONALE : Contingency management behavioral treatment approach provide immediate reward positive change behavior quit smoking . In protocol , contingency management form cash reward . A smoking cessation ( stop-smoking ) program combine contingency management bupropion counseling may effective help cancer survivor stop smoking . PURPOSE : Randomized clinical trial compare effectiveness bupropion counsel without contingency management help cancer survivor stop smoking .</brief_summary>
	<brief_title>Bupropion Counseling With Without Contingency Management Enhance Smoking Cessation Treating Cancer Survivors Who Continue Smoke</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare feasibility multi-component smoking cessation intervention comprise bupropion counsel without contingency management ( cash reward ) cancer survivor continue smoke . - Compare 7-day point-prevalence abstinence rate patient treat smoke cessation intervention . Secondary - Determine characteristic patient predict success quit smoking . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 smoking cessation intervention arm . - Arm I : Patients receive oral bupropion twice daily week 1-12 brief practical counseling ( i.e. , problem-solving strategy , stimulus control , stress management , social support ) week 1-6 . - Arm II : Patients receive treatment arm I contingency management ( i.e. , monetary reinforcement smoking ) week 1-6 . In arm , treatment continue absence unacceptable toxicity . Patients follow 12 24 week completion smoke cessation intervention . PROJECTED ACCRUAL : A total 100 patient ( 50 per intervention arm ) accrue study within 8 month .</detailed_description>
	<mesh_term>Bupropion</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer least 6 month study entry No carcinoma situ cervix , basal cell squamous cell skin cancer , CNS tumor Smoking history least 2 year Smoked cigarette daily past 30 day Completed prior cancer treatment least 6 month , 5 year study entry Concurrent tamoxifen allow PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Platelet count ≥ 100,000 450,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 2 time upper limit normal Bilirubin ≤ 2.0 mg/dL Renal Creatinine &lt; 2.0 mg/dL Cardiovascular No unstable cardiovascular disease , include follow : Highgrade atrioventricular block Neurocardiogenic syncope Unstable angina Uncompensated congestive heart failure Poorly control hypertension Other Not pregnant nursing Negative pregnancy test Able undergo peripheral blood draw No portacath Hickman catheters Planning reside Washington D.C. metro area least 1 year study entry Willing undergo urine test cotinine level breath test carbon monoxide monitoring No significant physical psychological disability would preclude study participation No known allergy bupropion Baseline urine drug screen negative Prescribed pain medication allow None follow predispose factor may increase risk seizure bupropion use : History seizure Alcohol use &gt; 4 oz/day History close head injury History eat disorder CNS infection No poorly control diabetes PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy See Disease Characteristics Radiotherapy Not specify Surgery Not specify Other At least 2 year since prior alcohol abuse substance abuse therapy ( except tobacco use dependence ) More 14 day since prior monoamine oxidase ( MAO ) inhibitor No concurrent MAO inhibitor No concurrent bupropion ( Wellbutrin® Wellbutrin SR® ) No concurrent alcohol substance abuse disorder treatment No concurrent nicotine replacement therapy No concurrent medication low seizure threshold ( e.g. , theophylline shortacting benzodiazepine ) No use tobacco product ( 1 time per week ) cigarette</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>cancer survivor</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>